ConforMIS
ConforMIS is a medical technology company that designs and manufactures patient-specific knee implants using 3D imaging from CT scans.
Secondary Market Price
How ConforMIS Measures Up
To help you manage your ConforMIS equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of ConforMIS's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future ConforMIS Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for ConforMIS's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
ConforMIS is a medical technology company that designs, manufactures, and sells patient-specific knee replacement implants. Using a patient’s CT scan, the company creates a 3D model to produce a custom implant, such as its iTotal knee replacement system, that is designed to match an individual's unique anatomy. The process also includes customized, single-use surgical instruments delivered in a pre-sterilized kit. ConforMIS was founded in 2004 in Billerica, Massachusetts, by Dr. Philipp Lang, who was dissatisfied with the limitations of traditional, symmetric implant designs. Since its founding, the company has grown internationally, provided over 137,000 implants, and its technology is supported by more than a decade of clinical evidence.
While the company has not publicly released specific future plans or recent announcements, its stated focus is on continued innovation in personalized knee replacement and helping patients resume daily activities. The company's products have been featured in over 50 clinical studies and more than 30 peer-reviewed publications. In the United Kingdom, ConforMIS has also received a '7A Performance ODEP rating' from the Orthopaedic Data Evaluation Panel, which reflects its established use within the orthopedics field.
- Aeris Capital
- AGC Equity Partners
- Axel Johnson Inc.
- Co-Founder, Philipp Lang
- Co-Founder, Daniel Steines
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is ConforMIS worth joining?
Evaluating whether to join a private company requires analyzing its potential future value, which can be a complex undertaking. Platforms like Prospect use proprietary models and VC-grade data to help you forecast your potential equity's value and make a more informed career decision.
What should I do with my ConforMIS stock?
Deciding what to do with your private company stock involves creating a strategy for exercising options and selling shares to maximize your returns. Prospect can build a customized, multi-year option exercise strategy to help you manage your equity and minimize your tax burden.
Can you sell ConforMIS stock?
Selling stock in a private company is often possible through secondary markets or company-approved tender offers. Tender offer tools from platforms like Prospect can help you navigate these liquidity events and decide how much to sell in a tax-optimal way.
How can I find the value of my ConforMIS stock?
The current value of private stock is typically determined by the company's 409A valuation, but its future potential is harder to gauge. Prospect uses predictive models trained on venture capital data to help you forecast the future value of your shares.
What is ConforMIS's equity worth?
The total worth of your equity depends on the company's valuation and your personal tax situation, which determines your after-tax gains. Platforms like Prospect help you understand the full picture by forecasting your equity's potential value and creating strategies to maximize your post-tax returns.
What is ConforMIS's stock ticker symbol?
As a private company, ConforMIS does not have a stock ticker symbol because its shares are not traded on public stock exchanges. Managing equity in a private company requires different tools and strategies than public stock investing.
Can I buy or sell ConforMIS stock?
Selling private stock is sometimes possible through tender offers or secondary markets, while buying is typically restricted to employees receiving equity or accredited investors. Platforms like Prospect can help employees manage their existing equity and navigate opportunities to sell.
What is the criteria to buy or invest in ConforMIS stock?
Investing in a private company like ConforMIS is generally limited to employees receiving equity compensation or accredited investors participating in private funding rounds. These investment opportunities are not typically available to the general public.
